We are live on ! Find out more
ENVB icon

Enveric Biosciences
ENVB

11 hedge funds and large institutions have $107K invested in Enveric Biosciences in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

21% more capital invested

Capital invested by funds: $87.7K → $107K (+$18.9K)

0.84% more ownership

Funds ownership: 0.66% → 1.49% (+0.84%)

0% more funds holding

Funds holding: 11 → 11 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

Holders
11
Holders Change
–
Holders Change %
0%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$87.7K
2
Jones Financial Companies
Jones Financial Companies
Missouri
+$2.73K
3
UBS Group
UBS Group
Switzerland
+$1.96K
4
SS
SBI Securities
Japan
+$93

Top Sellers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
-$8.26K
2
TRCT
Tower Research Capital (TRC)
New York
-$2.22K
3
Bank of America
Bank of America
North Carolina
-$18

ENVB Hedge Fund Activity: Q1 2026 in Review

11 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q1 2026, worth a combined $107K — up 21% from $87.7K a quarter earlier.

Fund positioning in ENVB was balanced in Q1 2026: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 1 trimmed.

The largest buyer was Geode Capital Management, opening a new position worth an estimated $87.7K. The largest seller was Citigroup, exiting entirely with an estimated $8.26K sold.

  • 11 institutional investors held Enveric Biosciences (ENVB) as of Q1 2026, unchanged from Q4 2025.
  • Funds reported $107K of Enveric Biosciences stock for Q1 2026, up 21% quarter-over-quarter.
  • 2 funds opened new Enveric Biosciences positions in Q1 2026 and 2 closed out, a net change of 0 holders.
  • The largest Enveric Biosciences buyer in Q1 2026 was Geode Capital Management, an estimated $87.7K added.
  • The largest Enveric Biosciences seller in Q1 2026 was Citigroup, an estimated $8.26K sold.

Based on aggregated 13F filings for Q1 2026.